MannKind Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference

On August 30, 2019 MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, reported that it will be featured as a presenting company at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 12:05 pm (ET) at the Lotte New York Palace Hotel in New York City (Press release, Mannkind, AUG 30, 2019, View Source [SID1234539150]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Michael Castagna, Chief Executive Officer, of MannKind Corporation, will provide an overview of the Company’s business during the live presentation. Steven B. Binder, Chief Financial Officer, will participate in one-on-one meetings with investors who are registered to attend the conference.

The presentation will be webcast live. Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company’s website at View Source The webcast replay will remain available for 14 days following the live presentation.